- Trial phase
- Phase 1
- Time to market
- Unknown, still in Phase 1; if successful, Phase 2/3 trials and regulatory review would take several years
- Why 4/10
- MGC026 is a Phase 1 asset with no pivotal readout or PDUFA in the next ~12 months. The next hard catalyst is the mid-2027 data update (~8 months out), which is not a binary regulatory or pivotal event. The drug is a key pipeline asset but MacroGenics also has other programs (lorigerlimab, MGC030), so MGC026 is not a single-asset binary.
Watch for the early 2027 initiation of the MGC026 + pembrolizumab front-line SCCHN combo study and the mid-2027 Phase 1 data update. The stock's $2.25 price vs. $8 mean analyst target suggests the market is pricing in significant pipeline risk. Monitor competitive B7-H3 ADC data from I-DXd and HS-20093 as benchmarks.
Price Chart
Executive Summary
MGC026 is MacroGenics' B7-H3-directed antibody-drug conjugate (ADC) currently in Phase 1 development. At ESMO 2026, the company reported interim data showing a 27% best overall response rate (6/22) in heavily pretreated SCCHN patients with no treatment-related discontinuations, a competitive profile versus other B7-H3 ADCs (I-DXd 14%, HS-20093 17%). The company plans to initiate a front-line combo study with pembrolizumab in early 2027 and provide the next data update mid-2027. MacroGenics trades at ~$2.25 (market cap ~$229M) with a mean analyst price target of $8, reflecting ~278% implied upside. However, MGC026 is still early-stage (Phase 1), the B7-H3 ADC space is increasingly competitive, and the company has no approved products, relying on its pipeline and the recent $122.5M manufacturing sale for funding.
How It Works
MGC026 is an antibody-drug conjugate (ADC), a targeted cancer therapy that works like a guided missile. One part of the drug (the antibody) binds to a protein called B7-H3 that is found on the surface of many cancer cells, and the other part delivers a chemotherapy payload directly inside those cells. This approach aims to kill cancer cells while sparing healthy tissue.
Trial Status
Interim Phase 1 data for MGC026 in squamous cell carcinoma of the head and neck (SCCHN) were presented at ESMO 2026. The dose-escalation and expansion cohorts are ongoing. A Simon's 2-stage monotherapy cohort (n=40) is enrolling. The company plans to initiate a front-line SCCHN combination study with pembrolizumab in early 2027, with the next data update expected mid-2027.
The Two-Sided Case
Upcoming Catalysts
- Early 2027: Initiation of front-line SCCHN combo study with pembrolizumab
- Mid-2027: Next MGC026 Phase 1 data update
- Simon's 2-stage monotherapy cohort (n=40) enrollment completion and data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MACROGENICS INC 8-K MGNX ·Originating report